Keryx Biopharmaceuticals, Inc. Reports Unaudited and Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018
Keryx Biopharmaceuticals, Inc. reported unaudited and consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported total revenues of $28,036,000 compared to $14,996,000 for the same period a year ago. Operating loss was $14,686,000 compared to $23,719,000 for the same period a year ago. Loss before income taxes were $16,995,000 compared to $23,478,000 for the same period a year ago. Net loss was $16,995,000 or $0.14 per basic and diluted share compared to $23,498,000 or $0.20 per basic and diluted share for the same period a year ago.
For the nine months, the company reported total revenues of $75,536,000 compared to $41,959,000 for the same period a year ago. Operating loss was $57,589,000 compared to $70,679,000 for the same period a year ago. Loss before income taxes were $61,043,000 compared to $132,951,000 for the same period a year ago. Net loss was $60,409,000 or $0.50 per basic and diluted share compared to $133,011,000 or $1.18 per basic and diluted share for the same period a year ago.